Valley Brook Capital Group Inc. Has $2.47 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Valley Brook Capital Group Inc. grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,660 shares of the medical research company’s stock after buying an additional 150 shares during the quarter. Thermo Fisher Scientific makes up 2.1% of Valley Brook Capital Group Inc.’s portfolio, making the stock its 8th largest position. Valley Brook Capital Group Inc.’s holdings in Thermo Fisher Scientific were worth $2,473,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in TMO. Raleigh Capital Management Inc. increased its holdings in shares of Thermo Fisher Scientific by 49.1% in the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 27 shares in the last quarter. Cedar Mountain Advisors LLC raised its position in shares of Thermo Fisher Scientific by 107.0% during the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock worth $47,000 after acquiring an additional 46 shares during the last quarter. Operose Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 250.0% during the third quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock valued at $53,000 after acquiring an additional 75 shares during the period. Financial Connections Group Inc. acquired a new stake in Thermo Fisher Scientific in the fourth quarter worth about $53,000. Finally, Valley National Advisers Inc. lifted its position in Thermo Fisher Scientific by 40.5% during the 3rd quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 32 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of recent research reports. JPMorgan Chase & Co. boosted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Evercore ISI increased their price target on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. HSBC lifted their price objective on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Citigroup started coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $607.35.

Thermo Fisher Scientific Stock Up 0.2 %

NYSE TMO traded up $1.13 on Friday, reaching $572.38. The company had a trading volume of 1,749,670 shares, compared to its average volume of 1,409,187. The company’s fifty day moving average is $575.39 and its 200-day moving average is $533.63. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The firm has a market capitalization of $218.48 billion, a price-to-earnings ratio of 36.71, a price-to-earnings-growth ratio of 2.37 and a beta of 0.80. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The business had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.64 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a $0.39 dividend. The ex-dividend date was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now owns 49,155 shares in the company, valued at $27,311,992.65. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now owns 1,207 shares in the company, valued at $660,192.79. The disclosure for this sale can be found here. In the last three months, insiders have sold 62,277 shares of company stock worth $35,373,364. Insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.